Previous 10 | Next 10 |
2023-12-14 05:55:40 ET Related stock stories: Adobe Inc. (ADBE) Q4 2023 Earnings Call Transcript Adobe: The Party Already Ended (Downgrading To Hold) Adobe Just Keeps Rising: How To Prepare For Q4 Earnings Adobe in charts: Creative Cloud revenue climbs 12% fr...
2023-12-13 16:59:17 ET Gainers: Codexis ( CDXS ) +16% . Nubia Brand International ( NUBI ) +13% . E.W. Scripps Company ( SSP ) +5% . WAVE Life Sciences ( WVE ) +5% . Losers: Amtech Systems ( ASYS ) -31% . Mont...
2023-12-13 16:20:24 ET More on Codexis, Danaher, etc. Danaher Corporation (DHR) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Danaher Corporation: A Good Contrarian Bet Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles Go...
REDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins fo...
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineer...
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023, to discuss the growth of RNA interference (RNAi) therapeutics as a modality, the manufacturing l...
2023-12-10 13:04:00 ET More on AbCellera Biologics, Absci, etc. AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Certara, Inc. 2023 Q3 - Results - Earnings Call Prese...
2023-11-29 14:46:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit m...
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA in...
2023-11-22 23:31:20 ET Summary ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of conviction relative to its main holdings. The f...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic man...
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotid...